What a Microbiome Diversity Score Actually Means

Beta diversity is the other kind, less often shown to consumers: a measure of how different your community is from another sample — from the average of a reference population, or from your own earlier test. It is the more useful measure for tracking change over time, and the less useful one for a single result, because it only says "different," not "worse."

Some reports render this as "your microbiome is similar to people who..." — a comparison against clusters in the company's database. Those are correlations within a customer base, and they are not a diagnosis.

Diet, above everything. Fiber from varied plant sources is the strongest single predictor of alpha diversity in large population studies — the number of different plants a person eats in a week tracks the score more closely than any other factor. Antibiotics lower it, sharply and for months. Age lowers it, gradually. Obesity, a Western low-fiber diet, chronic alcohol, and some medications (acid suppressants among them) are associated with lower scores. Exercise, sleep and living with a dog are associated with higher ones.

And the sample. A single stool sample varies from day to day in the same person by an amount comparable to the differences between people, and the method — which region of which gene is sequenced, how the sample is stored, which reference database the laboratory uses — changes the result. The main page is honest that the test is a snapshot with a wide margin.

Because low diversity is a feature of many conditions and a diagnosis of none. Inflammatory bowel disease, obesity, type 2 diabetes, irritable bowel syndrome and recent antibiotics all associate with lower alpha diversity in population studies — which means a low score narrows nothing. It is a property of the population, not a test for a disease in a person, and no guideline uses a diversity score to diagnose or exclude anything.

Nor is high diversity proof of health. Some infections raise it; some people with gut disease have unremarkable scores; and a person eating an exemplary diet can have a modest score for reasons no one can explain. The correlation between diversity and health is real at the level of thousands of people and loose at the level of one.

The mistake the reports invite is to treat the score as a target — to buy a probiotic, or a fiber product, or a "diversity protocol," to move it. Probiotics rarely change alpha diversity at all; they add a strain that usually does not persist. Fiber and plant variety do move it, and are worth doing for reasons that have nothing to do with the number.

Look at the score, note it, and then look past it. The more useful parts of a report are the ones the main page describes: which groups dominate and whether any is unusually abundant or absent; the inferred functional capacity, particularly for short-chain fatty acid production; and — on a stool panel rather than a sequencing test — the inflammation and digestion markers that actually change a clinical decision.

A low score in a person with symptoms is a prompt to look at diet, recent antibiotics and the markers above. A low score in a person without symptoms is a prompt to eat more plants. A high score is pleasant and proves little. And a score that changes between two tests a year apart, after a deliberate change in diet, is the one use of the number that is worth the test: it is your own baseline, compared with your own follow-up, on the same method.